Newsletter Vol. 2, No. 2 References

PDE5 INHIBITORS ARE SAFE AND EFFECTIVE: ADVERSE EVENTS ARE MILD
AND TRANSIENT

References:

1. Viagra^® (sildenafil) prescribing information. Pfizer Inc: New York, NY; 2005.

2. Cialis^® (tadalafil) prescribing information. Lilly ICOS LLC: Indianapolis, Ind and Bothell, Wash; 2005.

3. Levitra^® (vardenafil) prescribing information. Bayer Pharmaceuticals Corp: West Haven, Conn; 2005.

4. Morales A, Gingel C, Collins M, Wicker PA, Osterloh IH. Clinical safety of oral sildenafil citrate (VIAGRA™) in the treatment of erectile dysfunction. Int J Impot Res. 1998;10:69-74.

5. Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002;168:1332-1336.

6. Montorsi F, Verheyden B, Meuleman E, et al. Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction. Eur Urol. 2004;45:339-345.

7. Porst H, Rosen R, Padma-Nathan H, et al, and the Vardenafil Study Group. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res. 2001;13:192-199.

8. Hellstrom WJG, Gittelman M, Karlin G, et al, for the Vardenafil Study Group. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl. 2002;23:763-771.

9. Stief C, Porst H, De Tejada IS, Ulbrich E, Beneke M, for the Vardenafil Study Group. Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction. Int J Clin Pract. 2004;58:230-239.

10. Hatzichristou D. Phosphodiesterase 5 inhibitors and nonarteritic anterior ischemic optic neuropathy (NAION): coincidence or causality? J Sex Med. 2005;2:751-758.

11. Seftel AD. Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. Clin Cardiol. 2004;27(suppl I):I-14-I-19.

12. Hellstrom WJG, Kendirci M. PDE-5 inhibitors and NAION. Medscape Urology. Available at: http://www.medscape.com/viewarticle/508658. Accessed April 7, 2006.

13. Buono LM, Foroozan R, Sergott RC, Savino PJ. Nonarteritic anterior ischemic optic neuropathy. Curr Opin Ophthalmol. 2002;13:357-361.

14. Sharlip ID. PDE5 inhibitors do not cause NAION. J Sex Med. 2006;3(suppl 2):80.

15. Hatzimouratidis K, Hatzichristou DG. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? Drugs. 2005;65:1621-1650.